Q-omics provides the consensus-scored USP9YP22 profile across patient tissues and cancer cell-line models. USP9YP22 expression is associated with patient survival in 10 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, USP9YP22 is differentially expressed in 2, with the highest sampling consensus in KIRC. Additionally, USP9YP22 RNA expression shows 3,396 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight ACC, KIRC, and STAD as cancer lineages where USP9YP22 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for USP9YP22 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes USP9YP22 survival associations across molecular data types. USP9YP22 RNA expression shows survival associations in the most cancer types (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible USP9YP22 RNA expression–survival associations across cancer types. High USP9YP22 expression shows unfavorable associations in ACC, OV, KIRP, HNSC, LUSC and STAD. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for USP9YP22 RNA expression.
This table summarizes USP9YP22 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for USP9YP22. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. USP9YP22 shows lower tumor expression in PRAD and higher tumor expression in KIRC. The KIRC box plot shows higher USP9YP22 RNA expression in tumor versus normal tissue (log2 FC = +0.048, t-test p = .005).
This table shows molecular features associated with USP9YP22 in patient tissues and cancer cell lines. In patient samples, USP9YP22 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
